Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A phase 3 trial just handed sacituzumab tirumotecan (sac-TMT) a notable win. The TroFuse-015 trial showed the TROP2-directed antibody-drug conjugate significantly improved overall survival vs. physician's choice chemotherapy in patients with advanced gastroesophageal adenocarcinoma who had received at least two prior therapies — making it the first TROP2-directed ADC to hit this milestone in a global phase 3 study for this cancer type.
Merck's sacituzumab tirumotecan (sac-TMT) has cleared a major hurdle in gastrointestinal oncology. The phase 3 TroFuse-015 trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall survival (OS) improvement over physician's choice chemotherapy in patients with locally advanced or metastatic gastroesophageal adenocarcinoma who had progressed on at least two prior regimens. The OS benefit held up consistently across patient subgroups, regardless of TROP2 expression level, and no new safety signals were identified.
There's a nuance worth noting: sac-TMT did not meet the trial's secondary endpoint of progression-free survival (PFS) by blinded independent central review, creating a notable OS–PFS discordance. Objective response rate showed a nominal improvement favoring sac-TMT, but this wasn't formally tested under the prespecified analysis plan. Full data are expected to be presented at an upcoming medical conference and submitted to regulatory authorities.
Key Takeaways:
Why it matters: Third-line treatment options for gastroesophageal adenocarcinoma are extremely limited, and survival outcomes are poor. An OS benefit from a novel ADC in this setting could reshape treatment algorithms — and with regulatory submissions on the horizon, sac-TMT may soon offer patients a meaningful new option.